1. Summary of study characteristics.
Study | Country | No. of patients | Age (range unless otherwise stated) | % predicted FEV1 (range ) unless otherwise stated | Intervention | Comparator | Duration of treatment |
Albert 2011 | United States of America | 1142 | 65 ‐ 66 | 39 ‐ 40 | Azithromycin 250 mg daily | Placebo | 12 months |
Banerjee 2005 | United Kingdom | 67 | 65.1 ‐ 68.1 | 42.5 ‐ 43.9 | Clarithromycin ‐ long‐acting Klaricid XL 500 mg daily | Placebo | 3 months |
Berkhof 2013 | Netherlands | 84 | 67 ‐ 68 | 47.4 ‐ 49.8 | Azithromycin 250 mg 3 times a week | Placebo | 12 weeks |
Brill 2015 | United Kingdom | 99 | 67.9 ‐ 70.4 | 44 ‐ 53 | Moxifloxacin 400 mg/day for 5 days every 4 weeks | Placebo | 13 weeks |
Doxycycline 100 mg daily | |||||||
Azithromycin 250 mg 3 times a week | |||||||
He 2010 | China | 36 | 68.8 ‐ 69.3 | 42.1 ‐ 44.3 | Erythromycin 125 mg 3 times a day | Placebo | 6 months |
Mygind 2010 | Denmark | 575 | 71 (median) | 38.4 (median) | Azithromycin 500 mg 3 days a month | Placebo | 36 months |
NCT00524095 (terminated; details given represent proposal) | Italy | 210 | 45 ‐ 85 | N/A | Azithromycin 500 mg 3 times a week for 6 months, then fluticasone 500 μg twice a day for 6 months | Usual care | 1 year |
Fluticasone 500 μg twice a day for 6 months, then azithromycin 500 mg 3 times a week for 6 months | |||||||
NCT02628769 (terminated; details given represent proposal) | United Kingdom | 5 | N/A | N/A | Solithromycin 400 mg daily | Placebo | 28 days |
Seemungal 2008 | United Kingdom | 109 | 66 ‐ 68 | 49.25 ‐ 50.55 | Erythromycin 250 mg twice a day | Placebo | 12 months |
Sethi 2010 | International | 1157 | 66.1 ‐ 66.6 | 40.6 ‐ 42.2 | Moxifloxacin 400 mg daily for 5 days every 8 weeks | Placebo | 48 weeks |
Shafuddin 2015 | Australia & New Zealand | 292 | 65.8 ‐ 67.6 | 32.53 ‐ 35.8 | Roxithromycin 300 mg daily and Doxycycline 100 mg daily | Placebo | 12 weeks |
Roxithromycin 300 mg daily | |||||||
Simpson 2014 | Australia | 30 | 69.9 ‐ 71.1 | 51.1 ‐ 56.5 | Azithromycin 250 mg daily | Placebo | 12 weeks |
Suzuki 2001 | Japan | 109 | 69.1 ‐ 71.7 | 1.3 ‐ 1.47 L | Erythromycin 200 ‐ 400 mg daily | Riboflavin 10 mg daily | Unclear |
Tan 2016 | China | 54 | 67.3 ‐ 69.3 | 42.1 ‐ 46.5 | Erythromycin 125 mg 3 times a day for 12 months | Placebo | 12 months |
Erythromcyin 125 mg 3 times a day for 6 months | |||||||
Uzun 2014 | Netherlands | 92 | 64.7 ‐ 64.9 | 44.2 ‐ 45 | Azithromycin 500 mg three times a week | Placebo | 12 months |
Wang 2017 | China | 86 | 70.54 ‐ 72.43 | Unclear | Azithromycin 250 mg daily | Simvastatin 20 mg daily | 6 months |
FEV1: forced expiratory volume in one second.